B-cell Malignancy, NHL

B-cell Malignancy, NHL

IND Enabling
Phase I
Phase II
Phase III
CAR T for CD19+ hematological cancers, (NCT05037669)
Sponsors:
University of Pennsylvania
Indicator
IND Enabling
Phase I
Phase II
Phase III
Indicator
IND Enabling
Phase I
Phase II
Phase III
Large B-Cell Lymphoma, LBCL, (NCT04416984)
Sponsors:
Allogene Therapeutics
IndicatorIndicator
IND Enabling
Phase I
Phase II
Phase III
Relapsed or Refractory B-cell Lymphoma, DLBCL, (NCT04026100)
Sponsors:
The First Affiliated Hospital of Nanjing Medical University
Indicator
IND Enabling
Phase I
Phase II
Phase III
Relapsed or Refractory B-cell Malignancies, (NCT03229876)
Sponsors:
Bioray Laboratories - Shanghai Bangyao Biotechnology Co., Ltd.
IND Enabling
Phase I
Phase II
Phase III
Relapsed or Refractory B-cell Malignancies, Non-Hodgkin lymphoma, NHL, (NCT04213469)
Sponsors:
Bioray Laboratories - Bangyao Biotechnology Co., Ltd. 
IND Enabling
Phase I
Phase II
Phase III
IndicatorIndicator
IND Enabling
Phase I
Phase II
Phase III
close
Search CRISPR Medicine